CELLAÏON Trademark

Trademark Overview


On Thursday, June 16, 2022, a trademark application was filed for CELLAÏON with the United States Patent and Trademark Office. The USPTO has given the CELLAÏON trademark a serial number of 79346877. The federal status of this trademark filing is REGISTERED as of Tuesday, March 5, 2024. This trademark is owned by Cellaïon, société anonyme. The CELLAÏON trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Cells originating from human tissue, for medical, clinical or veterinary use, namely, liver derived cells and stem cells or liver progenitor cells; pharmaceutical preparations in the field of liver derived cells and stem cells or liver progenitor cells for the treatment of diseases that require cell therapy medicinal products, namely, liver diseases, chronic biliary diseases, cholestatic diseases, age-related diseases, bone and cartilage disorders, pancreatic diseases, kidney diseases, pulmonary diseases, cardiovascular diseases, eye diseases, ocular diseases, organ injury, organ failure, blood coagulation disorders, Clarkson disease, diabetes, skin diseases, cancer, metabolic diseases, inflammatory diseases, inflammation, neurodegenerative diseases, fibrotic diseases, proliferative diseases, infectious diseases, autoimmune diseases, diseases with unwanted immune response, sepsis, sepsis induced diseases, cellular senescence; surgical implants comprised of living tissue grown from stem...

Biomedical research and development services in relation to the testing of biological samples to determine the presence and activity of stem cells, progenitor cells and liver cells, in particular, liver stem cells and liver progenitor cells
cellaÏon

General Information


Serial Number79346877
Word MarkCELLAÏON
Filing DateThursday, June 16, 2022
Status700 - REGISTERED
Status DateTuesday, March 5, 2024
Registration Number7318105
Registration DateTuesday, March 5, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 19, 2023

Trademark Statements


Goods and ServicesCells originating from human tissue, for medical, clinical or veterinary use, namely, liver derived cells and stem cells or liver progenitor cells; pharmaceutical preparations in the field of liver derived cells and stem cells or liver progenitor cells for the treatment of diseases that require cell therapy medicinal products, namely, liver diseases, chronic biliary diseases, cholestatic diseases, age-related diseases, bone and cartilage disorders, pancreatic diseases, kidney diseases, pulmonary diseases, cardiovascular diseases, eye diseases, ocular diseases, organ injury, organ failure, blood coagulation disorders, Clarkson disease, diabetes, skin diseases, cancer, metabolic diseases, inflammatory diseases, inflammation, neurodegenerative diseases, fibrotic diseases, proliferative diseases, infectious diseases, autoimmune diseases, diseases with unwanted immune response, sepsis, sepsis induced diseases, cellular senescence; surgical implants comprised of living tissue grown from stem cells or progenitor cells in the field of liver derived cells and stem cells or liver progenitor cells; transplants being living tissue in the form of liver derived cells and stem cells or liver progenitor cells; live organs and tissues for surgical purpose in the field of liver derived cells and stem cells or liver progenitor cells; surgical implants comprising living tissue grown from stem cells or progenitor cells in the field of liver derived cells and stem cells or liver progenitor cells; cell-based pharmaceutical preparations in the field of liver derived cells and stem cells or liver progenitor cells for the treatment of liver diseases, chronic biliary diseases, cholestatic diseases, age-related diseases, bone and cartilage disorders, pancreatic diseases, kidney diseases, pulmonary diseases, cardiovascular diseases, eye diseases, ocular diseases, organ injury, organ failure, blood coagulation disorders, Clarkson disease, diabetes, skin diseases, cancer, metabolic diseases, inflammatory diseases, inflammation, neurodegenerative diseases, fibrotic diseases, proliferative diseases, infectious diseases, autoimmune diseases, diseases with unwanted immune response, sepsis, sepsis induced diseases, cellular senescence
Goods and ServicesBiomedical research and development services in relation to the testing of biological samples to determine the presence and activity of stem cells, progenitor cells and liver cells, in particular, liver stem cells and liver progenitor cells

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 12, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, August 12, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCellaïon, société anonyme
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressBE

Party NameCellaïon, société anonyme
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBE

Party NameCellaïon, société anonyme
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBE

Trademark Events


Event DateEvent Description
Monday, September 19, 2022CORRECTION TRANSACTION RECEIVED FROM IB
Thursday, August 11, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, August 12, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 16, 2022APPLICATION FILING RECEIPT MAILED
Thursday, December 1, 2022CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Sunday, March 19, 2023LIMITATION OF GOODS RECEIVED FROM IB
Wednesday, March 29, 2023ASSIGNED TO EXAMINER
Wednesday, April 5, 2023NON-FINAL ACTION WRITTEN
Thursday, April 6, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, May 23, 2023LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Saturday, June 3, 2023REFUSAL PROCESSED BY MPU
Saturday, June 3, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sunday, June 4, 2023NEW REPRESENTATIVE AT IB RECEIVED
Monday, June 26, 2023REFUSAL PROCESSED BY IB
Friday, October 20, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, October 20, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, October 21, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 29, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, November 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 29, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, December 19, 2023PUBLISHED FOR OPPOSITION
Tuesday, December 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, December 21, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, November 16, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 19, 2023NOTIFICATION PROCESSED BY IB
Thursday, December 21, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 5, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, March 5, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, March 11, 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Thursday, December 21, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, December 21, 2023TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, February 21, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, February 21, 2024NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Thursday, June 6, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, June 6, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB